Bullish
City Therapeutics
City Therapeutics, a Cambridge-based biotechnology company, launched in October 2024 with $135 million to develop next-generation RNA interference med...
BIIB
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (13)
Neutral (9)
Bearish (12)
Latest BIIB News
Bullish
Bullish
How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?
Shares of Biogen (BIIB) have outperformed the iShares Biotechnology ETF (IBB) over the past three months, year-to-date, and 52 weeks. The company, a l...
Neutral
This House of Representative Just Bought Up To $375K In Biogen Stock
Representative Maria Elvira Salazar of Florida recently purchased Biogen (NASDAQ: BIIB) stock worth between $115,010 and $375,000, with the transactio...
Bearish
Biogen to pay $18.9 million to settle investors' claims over Alzheimer's drug
Biogen has agreed to a $18.9 million settlement with investors who alleged the company misled them about the commercial readiness of its Alzheimer's d...
Neutral
This Biogen Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday
Needham analyst Ami Fadia has upgraded Biogen Inc. (NASDAQ: BIIB) from Hold to Buy, setting a price target of $255. Additionally, Wedbush analyst Stev...
Bullish
New Progress Toward Public Reimbursement of SKYCLARYS™ for People Living with Friedreich Ataxia in Quebec
Biogen Canada Inc. announced that the Institut national d'excellence en santé et en services sociaux (INESSS) has positively re-evaluated SKYCLARYS™ (...
Bearish
BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm has announced an investigation into Biogen Inc. (NASDAQ: BIIB) on behalf of investors who may have suffered losses due to potentia...
Bullish
Needham upgrades Biogen stock rating on pipeline outlook
Needham has upgraded Biogen Inc. to Buy from Hold, setting a price target of $255, citing an improved outlook for the company's commercial portfolio a...
Bullish
Needham Upgrades Biogen to Buy From Hold, Price Target Is $255
Needham has upgraded Biogen (BIIB) to a Buy rating from Hold, setting a price target of $255. This upgrade reflects a positive outlook on the biopharm...
Bullish
New Progress Toward Public Reimbursement of SKYCLARYS™ for People Living with Friedreich Ataxia in Quebec
Biogen Canada Inc. announced that Quebec's INESSS has positively re-evaluated SKYCLARYS™ (omaveloxolone), recognizing its therapeutic value and establ...
Bullish
Assessing Biogen (BIIB) Valuation After Breakthrough Therapy Status And Positive Lupus Trial Data
Biogen (BIIB) has received FDA Breakthrough Therapy Designation for its spinal muscular atrophy candidate salanersen and reported positive Phase 3 lup...
Neutral
Biogen’s Salanersen Win Adds New Dimension To SMA Growth Story
Biogen received FDA Breakthrough Therapy Designation for salanersen, an investigational once-yearly treatment for spinal muscular atrophy (SMA), which...
Neutral
FMR LLC holds 16.65M Biogen shares (BIIB) — 11.3% reported
FMR LLC has filed an amendment to its SCHEDULE 13G/A, reporting beneficial ownership of 16,652,974.82 shares of Biogen Inc. (BIIB) Common Stock, which...
Bearish
Lost Money on Biogen Inc. (BIIB)? Contact The Gross Law Firm Regarding an Ongoing Investigation
The Gross Law Firm is investigating potential securities fraud claims on behalf of Biogen Inc. (BIIB) investors who incurred losses. The firm, a natio...
Bullish
FDA names Biogen’s salanersen a breakthrough therapy for SMA
The FDA has granted breakthrough therapy designation to Biogen's salanersen, a potent new treatment for spinal muscular atrophy (SMA), indicating its ...
Bearish
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
Pomerantz LLP has launched an investigation into potential securities fraud or unlawful business practices by Biogen Inc. and its officers/directors. ...
Bullish
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy
Biogen's salanersen has received FDA Breakthrough Therapy Designation for spinal muscular atrophy (SMA), supported by Phase 1b data showing clinically...
Bullish
Biogen Announces Upcoming Kidney Presentations at European Renal Association and American Transplant Congresses
Biogen announced that fourteen abstracts related to its nephrology portfolio, including EMPAVELI® (pegcetacoplan) and investigational felzartamab, hav...
Neutral
A Look At Biogen (BIIB) Valuation After Earnings Beat And Parkinson’s Setback
Biogen (BIIB) is facing a mixed valuation after an earnings beat for Q1 2026 and the discontinuation of a Parkinson's drug candidate. While recent sto...
Bearish
Biogen and Denali halt BIIB122 trial for idiopathic Parkinson’s
Biogen and Denali Therapeutics have discontinued the clinical development of BIIB122 for idiopathic Parkinson's disease after the experimental therapy...
Research BIIB on:
Ad Space